- With Mayo Clinic gastroenterologist
Michael Picco, M.D.
read biographyclose windowBiography of
Michael Picco, M.D.
Michael Picco, M.D.
Dr. Michael F. Picco has been with Mayo Clinic since 1999. He is board certified in internal medicine and gastroenterology. Dr. Picco is an assistant professor of medicine at Mayo Clinic College of Medicine and a consultant in gastroenterology at Mayo Clinic in Florida.
He has authored numerous publications in the area of gastroenterology, including original research, editorials and textbook chapters. He works with a team of gastroenterologists that takes care of complex gastrointestinal conditions and has a particular interest in diarrheal illnesses and inflammatory bowel diseases (ulcerative colitis and Crohn's disease). He is also active in medical education in training new gastroenterologist and internists.
"MayoClinic.com is an invaluable resource for patients and their families," Dr. Picco said. "Informed patients are better able to participate in their own health care. A patient's participation is vital to the treatment of his or her disease. I hope to assist in helping patients understand their digestive problems and current treatments that are offered. This will allow for better communication between patients, their physicians and other health care professionals."
Dr. Picco serves as a reviewer of new research for several medical journals in the area of gastroenterology and is an active member of the American Gastroenterological Association, American College of Gastroenterology and the Crohn's & Colitis Foundation of America. He serves on numerous committees that address physician training, research and clinical practice in gastroenterology, both at Mayo Clinic and at the national level.
"Patients need to know about their disease, what to expect, the latest treatments and side effects so that they can make informed decisions about their health care. Gastrointestinal disease affects not only patients but also their families. My goal is to assure that our Web site provides accurate, reliable information and resources for patients. We must always provide the latest, most cutting-edge information to assist patients in dealing with their medical problems," Dr. Picco said.
Treatments and drugs (1)
- Cimzia: A new drug treatment for Crohn's disease?
Coping and support (1)
- Crohn's disease symptom: Is fatigue common?
Mayo Clinic Health Manager
Get free personalized health guidance for you and your family.
Get Started
About our e-newsletters
- Free e-newsletters
- Mayo Clinic expertise
- We do not share your e-mail address
Housecall, our weekly general-interest e-newsletter, keeps you up to date on a wide variety of health topics with timely, reliable, practical information, recipes, blogs, questions and answers with Mayo Clinic experts and more. Our biweekly topic-specific e-newsletters also include blogs, questions and answers with Mayo Clinic experts, and other useful information that will help you manage your health.
Housecall Archives
Mayo Clinic Housecall
Stay up to date on the latest health information.
What you get
- Free weekly e-newsletter
- Mayo Clinic expertise
- Recipes, tools and other helpful information
- We do not share your e-mail address
Question
Cimzia: A new drug treatment for Crohn's disease?
I just read about a new drug treatment for Crohn's disease called Cimzia. What can you tell me about it?
Answer
from Michael Picco, M.D.
In April 2008, certolizumab pegol (Cimzia) was approved by the Food and Drug Administration (FDA) for the treatment of Crohn's disease. Crohn's disease is a type of inflammatory bowel disease (IBD) in which the lining of your digestive tract becomes inflamed, causing severe diarrhea and abdominal pain. Cimzia is prescribed for people with moderate to severe Crohn's who haven't been helped by other treatments.
Like the Crohn's medications infliximab and adalumimab, Cimzia works by inhibiting a protein produced by your immune system known as tumor necrosis factor (TNF). TNF plays an important role in causing inflammation and complications of Crohn's disease.
When you first start taking Cimzia, you get one injection every two weeks. After three injections — if your doctor determines it's working for you — you receive just one injection a month.
Cimzia is effective in reducing the signs and symptoms of Crohn's, but it also carries risks. The most common side effects when taking Cimzia are headaches, upper respiratory infections, abdominal pain, injection site reactions and nausea. Like other medications that inhibit TNF, Cimzia affects your immune system and puts you at increased risk of becoming seriously ill with certain infections, such as tuberculosis. If you get an infection due to Cimzia, you'll have to stop taking the drug right away.
Next question
